A Phase 2 interventional study of Ibrutinib and rituximab in Follicular Lymphoma, B-cell Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-16.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ibrutinib in Lymphoma, Follicular — none open to participants now, 7 under way, 1 of them phase 3. ibrutinib · Lymphoma, Follicular.
Among the 24 studies testing ibrutinib in Lymphoma, Follicular, this one is the 7th largest by enrollment, is one of 6 that started in 2013, is one of 10 in phase 2, and was the 9th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 24 studies testing ibrutinib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 4
First in 2009; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 48 across the 24 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
23 studies in Lymphoma, Follicular by AbbVie: 1 open now, 4 under way, none of them phase 3. Of 19 finished, 15 (79%) have results posted.
Among the 23 studies in Lymphoma, Follicular by AbbVie, this one is the 14th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2013, is one of 5 in phase 2, and was the 13th registered.
AbbVie’s Lymphoma, Follicular studies by the year they started, since 2006.
3 of the studies testing ibrutinib in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT04450173University of California, DavisObinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing ibrutinib in Lymphoma, Follicular, from their registry updates:
Among AbbVie’s 23 in Lymphoma, Follicular:
This tab as a report to print or save as PDF → With an account.
This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).
This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with FL.
There are two study treatment arms.
Subjects enrolled into main study treatment arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
Subjects enrolled into the exploratory study treatment arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
Key Inclusion criteria:
Key Exclusion criteria:
History of other malignancies, except
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
Drug: Ibrutinib · Drug: rituximab
Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: rituximab
Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR)
Number of subjects achieving the best overall responses of CR or PR prior to the initiation of the next line of antineoplastic therapy as assessed by investigator per the Cheson et al, 2007 criteria. Target lesions are measured by CT, unless MRI is used as the assessment modality for lesions in anatomical locations not amenable to CT. CR is defined as the disappearance of all evidence of disease. PR is defined as \>=50% decrease in the sum of the product of the diameters of up to 6 largest dominant masses.
Time frame: Subjects in Arm 1 will have imaging assessments every 12 weeks for the first 8 assessments, then every 24 weeks. Subjects in Arm 2 will have imaging assessments starting at week 9, then every 12 weeks for 8 assessments, then every 24 weeks.
Duration of Response (DOR)
DOR is defined as the interval between the date of the first documented response (CR, PR) and the date of the first documented evidence of progressive disease (PD) or death. DOR will be analyzed for the subjects who achieve an overall response during the duration of study.
Time frame: Up to 45 months
Progression Free Survival (PFS)
PFS is defined as the time interval between the date of the first dose and the date of the earliest occurrence of PD or death due to any cause, whichever occurs first. PD is characterized by any new lesion or increase by \>=50% of previously involved sites from nadir.
Time frame: Up to 45 months
Overall Survival (OS)
Subjects will be followed for survival information up to three years after the last dose of study treatment, until new treatment or death, whichever occurs first. OS is defined as the duration of time from the date of the first dose to the date of death from any cause.
Time frame: Up to 45 months
Number of Participants With Treatment-emergent Adverse Events
Frequency, severity, and relatedness of treatment-emergent adverse events (AEs) Frequency of treatment-emergent AEs requiring discontinuation of study drug or dose reductions
Time frame: Up to 45 months
| Milestone | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| Started | 60 | 20 |
| Completed | 60 | 20 |
| Not completed | 0 | 0 |
Number of subjects achieving the best overall responses of CR or PR prior to the initiation of the next line of antineoplastic therapy as assessed by investigator per the Cheson et al, 2007 criteria. Target lesions are measured by CT, unless MRI is used as the assessment modality for lesions in anatomical locations not amenable to CT. CR is defined as the disappearance of all evidence of disease. PR is defined as \>=50% decrease in the sum of the product of the diameters of up to 6 largest dominant masses.
| Participants | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR) | 51 | 15 |
DOR is defined as the interval between the date of the first documented response (CR, PR) and the date of the first documented evidence of progressive disease (PD) or death. DOR will be analyzed for the subjects who achieve an overall response during the duration of study.
| months | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| Duration of Response (DOR) | NA (30.1602 to NA) | NA (24.6078 to NA) |
PFS is defined as the time interval between the date of the first dose and the date of the earliest occurrence of PD or death due to any cause, whichever occurs first. PD is characterized by any new lesion or increase by \>=50% of previously involved sites from nadir.
| months | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| Progression Free Survival (PFS) | 41.922 (31.6057 to 41.9220) | NA (23.4908 to NA) |
Subjects will be followed for survival information up to three years after the last dose of study treatment, until new treatment or death, whichever occurs first. OS is defined as the duration of time from the date of the first dose to the date of death from any cause.
| months | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| Overall Survival (OS) | 41.922 (NA to NA) | NA (NA to NA) |
Frequency, severity, and relatedness of treatment-emergent adverse events (AEs) Frequency of treatment-emergent AEs requiring discontinuation of study drug or dose reductions
| Participants | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| Subjects with any treatment-emergent AE | 60 | 20 |
| Subjects with any treatment-emergent AE Grade >=3 | 39 | 14 |
| Subjects with any treatment-related AE | 59 | 20 |
| Subjects with any treatment-related AE Grade >=3 | 29 | 14 |
| Subjects with any Ibrutinib-related AE | 57 | 20 |
| Subjects with any Ibrutinib-related AE Grade >=3 | 29 | 14 |
| Subjects with any Rituximab-related AE | 50 | 17 |
| Subjects with any Rituximab-related AE Grade >=3 | 11 | 7 |
| TEAE leading to ibrutinib dose reduction | 9 | 5 |
| TEAE Grade >=3 leading to Ibrutinib dose reduction | 6 | 4 |
| TEAE leading to witholding Rituximab | 1 | 1 |
| TEAE Grade >=3 leading to witholding Rituximab | 1 | 1 |
| TEAE leading to discontinuation of Ibrutinib | 14 | 2 |
| TEAE Grade >=3 leading to discontinuation of Ibrut | 11 | 1 |
| TEAE leading to discontinuation of Rituximab | 0 | 0 |
| TEAE Grade >=3 leading to discontinuation of Ritux | 0 | 0 |
| Subjects with any TE Serious Adverse Event (SAE) | 14 | 6 |
| Subjects with any TE SAE Grade >=3 | 13 | 5 |
| Ibrutinib-related SAEs | 6 | 4 |
| Ibrutinib-related SAEs Grade >=3 | 6 | 4 |
| Rituximab-related SAEs | 2 | 2 |
| Rituximab-related SAEs Grade >=3 | 2 | 2 |
Collected over 3 years, 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study Arm 1 | 4/60 (6.7%) | 14/60 (23.3%) | 60/60 (100%) |
| Exploratory Study Arm 2 | 0/20 (0%) | 6/20 (30%) | 20/20 (100%) |
| Event | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| PyrexiaGeneral disorders | 2/60 | 3/20 |
| DiarrhoeaGastrointestinal disorders | 0/60 | 2/20 |
| PneumoniaInfections and infestations | 2/60 | 2/20 |
| Rectal haemorrhageGastrointestinal disorders | 0/60 | 1/20 |
| Non-cardiac chest painGeneral disorders | 0/60 | 1/20 |
| Urinary tract infectionInfections and infestations | 1/60 | 1/20 |
| Clostridium difficile colitisInfections and infestations | 0/60 | 1/20 |
| InfluenzaInfections and infestations | 0/60 | 1/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/60 | 1/20 |
| TendonitisMusculoskeletal and connective tissue disorders | 0/60 | 1/20 |
| Event | Main Study Arm 1 | Exploratory Study Arm 2 |
|---|---|---|
| FatigueGeneral disorders | 41/60 | 15/20 |
| DiarrhoeaGastrointestinal disorders | 34/60 | 12/20 |
| StomatitisGastrointestinal disorders | 10/60 | 11/20 |
| NauseaGastrointestinal disorders | 29/60 | 10/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 20/60 | 9/20 |
| DizzinessNervous system disorders | 13/60 | 9/20 |
| ParaesthesiaNervous system disorders | 9/60 | 8/20 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 18/60 | 8/20 |
| Upper respiratory tract infectionInfections and infestations | 13/60 | 7/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 20/60 | 3/20 |
| Age, Categorical(Participants) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 42 | 12 | 54 |
| >=65 years | 18 | 8 | 26 |
| Age, Continuous(years) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| Median | 58.0 (32 to 84) | 55.0 (30 to 75) | 58.0 (30 to 84) |
| Sex: Female, Male(Participants) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| Female | 32 | 8 | 40 |
| Male | 28 | 12 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 57 | 17 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 56 | 18 | 74 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| United States | 60 | 20 | 80 |
| Baseline B-Symptoms(Participants) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| B-Symptoms present prior to first dose | 4 | 0 | 4 |
| B-Symptoms absent | 56 | 20 | 76 |
| Baseline Eastern Cooperative Oncology Group (ECOG) Score(Participants) | Main Study Arm 1 | Exploratory Study Arm 2 | Total |
|---|---|---|---|
| Baseline ECOG Score = 0 | 47 | 12 | 59 |
| Baseline ECOG Score = 1 | 13 | 8 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Dec 2013, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Rituximab